Pfizer CEO receives 44% pay rise

by IainBate 19. March 2012 14:46

Pfizer CEO receives 44% pay rise - Pharmaceutical Field Pfizer CEO Ian Read received a 44% rise in his total income last year as a reward for guiding the company in its first steps beyond the ‘patent cliff’.

Read, who was appointed CEO in December 2010, saw his salary and bonuses package rise to $25m.

Pfizer said in a regulatory filing that the company had survived the loss of exclusivity on its blockbuster drug Lipitor by cutting $1bn per year from its R&D budget.

Before taking over as CEO after Jeffrey Kindler’s resignation, Ian Read held several senior executive roles at Pfizer for 32 years, including global head of pharmaceuticals.

“Under the leadership of Ian Read, we set a course to redefine and strengthen Pfizer,” the filing claimed.

The US patent on Pfizer’s cholesterol-lowering drug Lipitor, the world’s bestselling pharmaceutical product, expired in November 2011. The company also faced pricing pressure on many products.

Read led a programme of R&D spending cuts that saw thousands of research jobs and many facilities axed, with the long-term goal of cutting $2bn from the company’s R&D budget.

According to the filing, Pfizer returned $15.2bn to shareholders through dividends and stock buybacks in 2011.

Another strategy announced by Read is the divestment of the company’s nutritional products and animal health units, which will be either sold or spun off and the money used to buy back company shares.

Read’s 2011 income package included a salary rise from $1.2m to $1.7m, while his cash incentive awards more than doubled to $3.5 million. His stock awards, stock option awards and pension compensation also increased significantly.

Spotlight on CRM

by IainBate 19. March 2012 14:29

SPOTLIGHT CRM - Pharmaceutical Field How do you view CRM: as a chore, as a way of saving effort, or as a valuable window on your customers’ world? Leading CRM vendors tell Pf where the pharmaceutical industry sometimes gets it wrong – and how a combination of new business thinking and new technology can turn customer data into powerful insight.

Customer Relationship Management (CRM) is more than an electronic system for data handling. It’s a well-established business strategy for collecting and utilising the most relevant information about the market. As such, it is a function of the whole company that lends itself well to an integrated commercial strategy. A glance at the industry’s news shows that customer and sales data affect every aspect of a pharmaceutical company. Moreover, how a company uses those data to develop its products and communicate their value to customers can have a significant impact on customer relationships.

But is CRM in danger of going stale? Has it become something that only sales people use, and even then not whole-heartedly? Is a perceived lack of progress with CRM due to problems with the technology, the people using it, or companies’ approach to it?

The answer, according to the specialist CRM suppliers Pf spoke with, is all three. But as they also told us, these drivers of fail need to change. A new ‘golden age’ of CRM is on the way.

Dead-end data
According to David Round, General Manager at Cegedim UK, the most common problem of CRM use in the pharma industry is poor awareness of its potential: “If you have a particular group of users who don’t feel the system works for them, and therefore don’t put in the richness of information that they could, that has a bigger impact on the CRM project as a whole.” Unless the company is using CRM to its best advantage, field sales professionals may lack confidence in it as a tool. 

In addition, Round argues, not every CRM system is fit for purpose: “Where technology can be a hindrance is where the way that it works is relatively fixed or determined in some dark room somewhere, and it doesn’t match the day to day process of the people who are using it. The technology, if it’s not designed correctly with the end users in mind, can actually contribute to a lack of return or a reduced return on investment for the CRM solution.”

Adam Nicholson, Commercial Director at Conigi, identifies four sources of CRM blues: CRM only seen as a sales team tool, thinking limited by previous CRM experiences, fear of the system’s complexity and (conversely) fear/perception that it cannot deal with new commercial realities. All of these, he says, are consequences of narrow thinking: “The reality is that if you pick the right vendor and the right solution, you have enough headroom for development to build what you need now and as your business changes.”
Not seeing the wood for the trees, the insights for the data, is another source of CRM frustration. Dan Goldsmith, General Manager at Veeva Europe, argues that the most successful pharma companies are able to derive “rich and insightful information” from CRM by moving “beyond the operational or transactional information” to a deeper analysis of customer behaviours – with the CRM supplier “not just supporting their business processes but helping them innovate the way they engage and architect the customer experience”. 

Nick Plank, Director, C&C Group, says that CRM systems, like pharma’s operational model, have evolved to meet the needs of a changing NHS in the past decade – and will evolve further as technology continues to advance. “Ten years ago, the environment was very much focused on the rep and in particular on the traditional one-to-one face-to-face style of territory organised sales forces. Fast forward to the present and CRM looks very different, with KAM structured teams engaging with customers on an account basis as opposed to a geographical brick structure, plus a variety of new stakeholders in CRM from medical development advisors to medical science liaison. A fully-integrated CRM accessible to multiple stakeholders is now essential if business functions throughout the enterprise are to have holistic visibility of the account and contribute data from their specific areas such as information gathered during digital engagement.”

Keep taking the tablets
All relevant stakeholders are agreed on the revolutionary importance of the iPad and similar tablet computers for CRM in the context of field sales. These devices take CRM out of the office and onto the road more effectively than ever before. They also have the power to support closed-loop marketing and related strategies, giving CRM a more dynamic role in the customer relationship and in the pharma company.

David Round comments: “I think that CRM is about to enter a pretty golden age, because the birth of the tablet computer and the iPad in particular means that the rep can use the system much more effectively on the go. Reps are more inclined to enter information just after the call than wait until they get home, and what the iPad does is give them the ability to record this information with much more richness and much quicker after the interaction. Obviously, mobile access to the internet is still limited in many medical locations, and for this reason, the CRM must be able to provide most of its functionality in an office mode. As many reps would point out – what’s the point of having a mobile CRM that only really works online?”

In addition, the iPad gives the field-based sales rep rapid access to market information at a time when the UK drug market is going through dramatic change. The ability to keep track of the changing customer base and to structure new relationships with new types of customer is essential, and new technology is vital for this. As Adam Nicholson observes: “Gone are the days when you had a linear customer relationship in place and a linear CRM system to manage that. With the changes in the NHS, you’re going to have to have dynamic processes in place and a dynamic solution to manage it as you move forward.”

The iPad is arguably the first technology to make mobile CRM an effective reality. Dan Goldsmith argues that “it really hasn’t been until the introduction of the iPad that we’ve seen both widespread adoption and significant results delivered to pharma”. There are three reasons for that, he says: the mainstream adoption of mobile technology, the industry’s new appetite for “advances in digital and interactive presentations with customers”, and the reliability and simplicity of the iPad itself – “the ideal device at the ideal time”.    

A recent IMS report highlighted the growing importance of embedded business intelligence within the fully-integrated CRM. “This is where hosted European sales data warehouses are particularly useful, because they reduce costs by providing a single integration for analytical CRM across Europe,” says Nick Plank. “A managed hosted European approach to analytical CRM means employees across Europe can access market intelligence online when and where they need it without installing software. It also aligns well with the current move from on-premise systems to Cloud CRM because analytical data can be passed directly to the operational vendor using site-to-site integration – giving reps access to information immediately, wherever they are, via their mobile CRM tools or mobile business intelligence apps.”

Building dynamic relationships
What makes for an effective CRM system? The answer depends on how the sales professional and the company use the system. CRM is not about customer data: it’s about customer relationships.
David Round emphasises the need for “human-centred design”: it’s essential for the CRM user to be able to see the data in context and react appropriately. He uses the analogy of a sat nav system: it’s a superb tool to get you through unknown territory, but you also have to keep your eyes on the road. So the best systems support customer relationships instead of providing an electronic surrogate for them.

Round also warns against being too well-informed. If a rep greets a new customer they have never met before with the words Hi, I’m Jo. How are your children Sally and Billy? the relationship will get off to a bad start. What the rep really needs is the relevant background information to understand the customer’s role and make proactive suggestions from the start.

As Adam Nicholson observes, the CRM system has to deliver insights at both the quick overview and the deeper insight level: “We are rich with data within the industry; the old challenge has always been how you turn that data into information. Successful solutions should allow an individual to look at their data at a top level when they need it, but give them the ability to drill down into the customer data or the sales data to gain more in-depth analysis when needed.” 

The best CRM solutions are able to serve the needs of the most ambitious sales professionals and companies. Dan Goldsmith comments that cutting-edge CRM systems are enabling “interactive presentations, delivering better segmentation and targeting down to a more individual level, as well as collecting more psychographic or behavioural information”. The ultimate (and realisable) goal is a “behavioural profile” of each customer that feeds back into the sales message and interaction.

The bigger picture
The closed-loop marketing model implied by this approach cannot begin and end with sales. Adam Nicholson speaks for all forward-thinking CRM vendors when he says: “If you really want to make CRM work, it’s about engaging all the functions, be that marketing, medical, regulatory or finance, because if you implement the theory of CRM it actually impacts and improves business processes across all the functions.”

If you started reading this article with the mental image of a lonely sales rep (that’s you, that is) wrestling with interminable on-screen figures on a laptop in a hotel room, or on a tiny mobile phone screen in a rail station café, maybe it’s time for you and your company to consider upgrading your hardware, software and probably footwear. New CRM systems are able to support an integrated strategy of commercial interaction at every level of your company, and mobile devices exist to make the most sophisticated CRM systems easily applicable wherever you are.

With the right CRM system, the right mobile platform and the right attitude, you can: research each customer’s needs and behaviours; gain up-to-date information on the rapidly changing customer base; be fully primed with the right clinical information and tailored marketing messages; read and record key information without eyestrain or signal problems; and fit the technology to your individual needs and your company’s business goals. It’s up to you.

Boehringer breaches ABPI Code

by IainBate 19. March 2012 14:03

Pharma Industry News Boehringer Ingelheim has breached the ABPI Code of Practice over the promotion of its type 2 diabetes drug Trajenta.

The Prescription Medicines Code of Practice Authority (PMCPA) ruled that Boehringer had breached five different clauses of the Code in a medical journal before Trajenta was granted a marketing authorisation.

The PMCPA deemed that Clauses 2, 3, 7, 9 and 12 of the industry’s rule book had all been breached.

As a result, Boehringer was the subject of a public reprimand in advertisements in the BMJ, The Pharmaceutical Journal and The Nursing Standard.

In total, Boehringer was found to have breached nine different parts of the Code: Clause 2 – Bringing discredit upon, and reducing confidence in, the pharmaceutical industry; Clause 3.1 – Promoting a medicine before the grant of a marketing authorisation.

Four aspects of Clause 7 – Information, claims and comparison – were breached, along with two aspects of Clause 9 – High Standards, Format, Suitability and Causing Offence, Sponsorship – and Clause 12.1 – Disguising promotional materials.

Neurology care ill-served by local control

by JoelLane 19. March 2012 13:47

Pf NHS News Dependence on local control for care of neurological conditions has resulted in poorer outcomes than if there were a nationally-led strategy, according to MPs.

A report by the Public Accounts Committee contrasts the “poorly co-ordinated” and inconsistent care of conditions such as Parkinson’s disease with the impact of national targets for cancer and stroke care.

An estimated two million people in the UK have a neurological condition, the report said, but the quality of care provided varies significantly between locations.

The National Service Framework (NSF) for long-term conditions, published in 2005, contained 11 quality indicators. However, there was no national baseline for services or outcomes and no monitoring of progress.

This contrasts with the NSFs for cancer and stroke treatment, which were nationally led to drive improvements.

The report noted that despite their complex needs, spending on social services for people with neurological conditions has not increased since 2006 and healthcare provision remains below the quality requirements set out in the NSF.

This failure is reflected by a 32% increase in emergency admissions and an increase in the rate of readmissions within 28 days from 11.2% to 14%.

Finally, the report observed that only 22% of people with Parkinson’s disease, multiple sclerosis or motor neurone disease have a personal care plan.

It recommended the appointment of a national clinical lead for neurology.

Committee chair Margaret Hodge MP said that for people with neurological conditions “individual care is often poorly co-ordinated and the quality of services received depends on where you live. Some areas simply don’t have enough expertise, both in hospitals and in the community.

“For this clinical area, the department left the implementation to local health commissioners but gave them no leadership at all. It set no baselines and failed to monitor progress. The present government needs to understand what went wrong here for the future.”

Oral cancer drugs affected by other medications

by JoelLane 19. March 2012 13:16

Pf clinical news Oral cancer drugs such as Glivec and Tarceva are negatively affected by other medications including steroids and antibiotics, according to a new US study.

The Medco Research Institute (MRI) has claimed that medications taken by as many as 75% of cancer patients interfere with the effects of oral kinase inhibitors, a major class of adjunctive cancer therapy.

The effect of the medication interference is to weaken the effectiveness of the anti-cancer treatment and/or increase its toxicity, the study found.

Oral kinase inhibitors, which suppress tumour cell metabolism, are widely prescribed for their ability to increase the effectiveness (and reduce effective dosage levels) of chemotherapy.

The MRI study, which looked at 4,617 cancer patients, found that 23–74% of them were being prescribed a medication that interfered with their oral cancer drug. Of these, 43% showed a reduction in the efficacy of the cancer drug and 68% showed an increase in its toxicity.

Oral kinase inhibitors include (UK trade names): Glivec (imatinib), Tarceva (erlotinib), Sprycel (dasatinib), Afinitor (everolimus), Tyverb (lapatinib), Tasigna (nilotinib), Votrient (pazopanib), Nexavar (sorafenib) and Sutent (sunitinib).

The medications that interfere with them, according to the study, are calcium channel blockers, antifungal agents, steroids, proton pump inhibitors and some antibiotics.

Dr Steve Bowlin, Senior Director at the MRI and co-author of the study, said: “Since these are drugs launched in the past decade for fairly small patient populations, we are learning more about how they are used in real-world settings as compared to traditional clinical trials that test safety and efficacy in a tightly-controlled environment.

“Oncologists are not always aware of other medications prescribed by other doctors and vice-versa, which can pose a real hazard for their patients on oral cancer therapies.”

‘Moderate’ growth predicted for UK pharma – report

by IainBate 19. March 2012 12:41

Pharma Industry News

The UK pharmaceutical market is expected to experience growth of just 0.4% until 2015, a new report says.

Research and Markets’ The Pharmaceutical Market: UK predicts growth of less than one per cent in real terms due to the effects of the recession, cuts in public spending and NHS savings targets.

The report says that tighter healthcare spending could have a negative impact on the market with the NHS having less capital to spend on new or expensive drugs.

The NHS has been challenged with making a total of £20 billion in annual efficiency and productivity savings by 2014.

However, despite these cost-cutting measures, the UK Government has released additional funding through its Cancer Drugs Fund – which came into force in April 2011.

The report notes the impact of value-based pricing (VBP) in order to promote innovation and ensure better access for patients to new medicines when it is introduced in 2013.

A VBP system will be implemented for new active substances introduced from 1 January 2014 onwards. Existing medicines could be included in the system, but generics are expected to be excluded from the scheme.

As it would not be feasible to carry out a VBP assessment for each new medicine entering the market, the report says, interim arrangements are expected to run alongside the new scheme – which is likely to resemble the existing PPRS, the report predicts.

The introduction of the Government’s Patent Box is expected to generate growth in the industry, the report says. GSK has already confirmed it will invest more than £500m when the programme is introduced, which will lead to the creation of around 1,000 new jobs.

Despite the modest growth expected in the UK pharmaceutical market, the outlook is still brighter than the European counterpart. In a similar report, the European pharmaceuticals market had total revenues of $213.9 billion in 2010 – representing a compound annual growth rate of 4.6% from 2006 to 2010.

But the market is forecast to decelerate by a compound annual growth rate of 3.2% between 2010 and 2015, the report anticipates. This will result in the market value being approximately $250.3 billion by the end of 2015.

Pfizer, the report says, will lead the European pharmaceutical markets, with a market share of 6.7%.

Medtech Features Test 1

by Admin 19. March 2012 12:26

test

Tags:

TextBox

Tag cloud

Calendar

<<  March 2012  >>
MoTuWeThFrSaSu
2728291234
567891011
12131415161718
19202122232425
2627282930311
2345678

View posts in large calendar